Treatment with IM, BMP inhibitors or in combination, ±BMP4 stimulation, resulted in a significant reduction in AVCR1 (ALK2) expression (Fig. 6d–ii), with no changes in BMPR1A (ALK3) and BMPR1B (ALK6) (data not shown) in CML-iPSCs. This evidence concerns the gene ACVR1 and chronic myelogenous leukemia, BCR-ABL1 positive.